AAAAAA

   
Results: 1-19 |
Results: 19
THE M184V MUTATION IN HIV-1 REVERSE-TRANSCRIPTASE (RT) CONFERRING LAMIVUDINE RESISTANCE DOES NOT RESULT IN BROAD CROSS-RESISTANCE TO NUCLEOSIDE ANALOG RT INHIBITORS
Authors: MILLER V STURMER M STASZEWSKI S GROSCHEL B HERTOGS K DEBETHUNE MP PAUWELS R HARRIGAN PR BLOOR S KEMP SD LARDER BA
Citation: V. Miller et al., THE M184V MUTATION IN HIV-1 REVERSE-TRANSCRIPTASE (RT) CONFERRING LAMIVUDINE RESISTANCE DOES NOT RESULT IN BROAD CROSS-RESISTANCE TO NUCLEOSIDE ANALOG RT INHIBITORS, AIDS, 12(7), 1998, pp. 705-712
REBOUND OF PLASMA HIV VIRAL LOAD FOLLOWING PROLONGED SUPPRESSION WITHCOMBINATION THERAPY
Authors: MONTANER JSG HARRIS M MO T HARRIGAN PR
Citation: Jsg. Montaner et al., REBOUND OF PLASMA HIV VIRAL LOAD FOLLOWING PROLONGED SUPPRESSION WITHCOMBINATION THERAPY, AIDS, 12(11), 1998, pp. 1398-1399
COMPARISON OF COSTS OF STRATEGIES FOR MEASURING LEVELS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RNA IN PLASMA BY USING AMPLICOR AND ULTRA DIRECT ASSAYS
Authors: RABOUD JM SEMINARI E RAE SL HARRIGAN PR HOGG RS CONWAY B SHERLOCK C SCHECHTER MT OSHAUGHNESSY MV MONTANER JSG
Citation: Jm. Raboud et al., COMPARISON OF COSTS OF STRATEGIES FOR MEASURING LEVELS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RNA IN PLASMA BY USING AMPLICOR AND ULTRA DIRECT ASSAYS, Journal of clinical microbiology (Print), 36(11), 1998, pp. 3369-3371
A NOVEL POLYMORPHISM AT CODON-333 OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE CAN FACILITATE DUAL RESISTANCE TO ZIDOVUDINEAND L-2',3'-DIDEOXY-3'-THIACYTIDINE
Authors: KEMP SD SHI CF BLOOR S HARRIGAN PR MELLORS JW LARDER BA
Citation: Sd. Kemp et al., A NOVEL POLYMORPHISM AT CODON-333 OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE CAN FACILITATE DUAL RESISTANCE TO ZIDOVUDINEAND L-2',3'-DIDEOXY-3'-THIACYTIDINE, Journal of virology, 72(6), 1998, pp. 5093-5098
RELATIVE REPLICATIVE FITNESS OF ZIDOVUDINE-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES IN-VITRO
Authors: HARRIGAN PR BLOOR S LARDER BA
Citation: Pr. Harrigan et al., RELATIVE REPLICATIVE FITNESS OF ZIDOVUDINE-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES IN-VITRO, Journal of virology, 72(5), 1998, pp. 3773-3778
PHARMACOKINETICS AND ANTIRETROVIRAL ACTIVITY OF LAMIVUDINE ALONE OR WHEN COADMINISTERED WITH ZIDOVUDINE IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-INFECTED PREGNANT-WOMEN AND THEIR OFFSPRING
Authors: MOODLEY J MOODLEY D PILLAY K COOVADIA H SABA J VANLEEUWEN R GOODWIN C HARRIGAN PR MOORE KHP STONE C PLUMB R JOHNSON MA
Citation: J. Moodley et al., PHARMACOKINETICS AND ANTIRETROVIRAL ACTIVITY OF LAMIVUDINE ALONE OR WHEN COADMINISTERED WITH ZIDOVUDINE IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-INFECTED PREGNANT-WOMEN AND THEIR OFFSPRING, The Journal of infectious diseases, 178(5), 1998, pp. 1327-1333
DUAL RESISTANCE TO ZIDOVUDINE AND LAMIVUDINE IN PATIENTS TREATED WITHZIDOVUDINE-LAMIVUDINE COMBINATION THERAPY - ASSOCIATION WITH THERAPY FAILURE
Authors: MILLER V PHILLIPS A ROTTMANN C STASZEWSKI S PAUWELS R HERTOGS K DEBETHUNE MP KEMP SD BLOOR S HARRIGAN PR LARDER BA
Citation: V. Miller et al., DUAL RESISTANCE TO ZIDOVUDINE AND LAMIVUDINE IN PATIENTS TREATED WITHZIDOVUDINE-LAMIVUDINE COMBINATION THERAPY - ASSOCIATION WITH THERAPY FAILURE, The Journal of infectious diseases, 177(6), 1998, pp. 1521-1532
PROSPECTIVE LONGITUDINAL ANALYSIS OF VIRAL LOAD AND SURROGATE MARKERSIN RELATION TO CLINICAL PROGRESSION IN HIV TYPE 1-INFECTED PERSONS
Authors: BRUISTEN SM FRISSEN PHJ VANSWIETEN P HARRIGAN PR KINGHORN I LARDER B WEIGEL HM DEVRIES E REGEZ RM HENRICHS JH KOOT M HUISMAN JG
Citation: Sm. Bruisten et al., PROSPECTIVE LONGITUDINAL ANALYSIS OF VIRAL LOAD AND SURROGATE MARKERSIN RELATION TO CLINICAL PROGRESSION IN HIV TYPE 1-INFECTED PERSONS, AIDS research and human retroviruses, 13(4), 1997, pp. 327-335
THE SAFETY AND ANTIVIRAL EFFECT OF 1592U89, ALONE AND IN COMBINATION WITH ZIDOVUDINE IN HIV-1-INFECTED PATIENTS WITH CD4-500 CELLS( COUNTS 200)MM(3)/
Authors: SONNERBORG A LANCASTER D TORRES R THOMPSON M SAAG M SCHOOLEY R MULDER J GAZZARD B DAQUILA R GURGUL M FEINBERG J SANTIN M LANG W HARRIGAN PR STEEL H TORTELL S ROMERO C
Citation: A. Sonnerborg et al., THE SAFETY AND ANTIVIRAL EFFECT OF 1592U89, ALONE AND IN COMBINATION WITH ZIDOVUDINE IN HIV-1-INFECTED PATIENTS WITH CD4-500 CELLS( COUNTS 200)MM(3)/, AIDS, 10, 1996, pp. 41-41
SAFETY AND EFFICACY OF LAMIVUDINE-ZIDOVUDINE COMBINATION THERAPY IN ZIDOVUDINE-EXPERIENCED PATIENTS - A RANDOMIZED CONTROLLED COMPARISON WITH ZIDOVUDINE MONOTHERAPY
Authors: STASZEWSKI S LOVEDAY C PICAZO JJ DELLAMONICA P SKINHOJ P JOHNSON MA DANNER SA HARRIGAN PR HILL AM VERITY L MCDADE H
Citation: S. Staszewski et al., SAFETY AND EFFICACY OF LAMIVUDINE-ZIDOVUDINE COMBINATION THERAPY IN ZIDOVUDINE-EXPERIENCED PATIENTS - A RANDOMIZED CONTROLLED COMPARISON WITH ZIDOVUDINE MONOTHERAPY, JAMA, the journal of the American Medical Association, 276(2), 1996, pp. 111-117
HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 DRUG SUSCEPTIBILITY DURING ZIDOVUDINE (AZT) MONOTHERAPY COMPARED WITH AZT PLUS 2',3'-DIDEOXYINOSINE OR AZT PLUS 2',3'-DIDEOXYCYTIDINE COMBINATION THERAPY
Authors: LARDER BA KOHLI A BLOOR S KEMP SD HARRIGAN PR SCHOOLEY RT LANGE JMA PENNINGTON KN STCLAIR MH
Citation: Ba. Larder et al., HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 DRUG SUSCEPTIBILITY DURING ZIDOVUDINE (AZT) MONOTHERAPY COMPARED WITH AZT PLUS 2',3'-DIDEOXYINOSINE OR AZT PLUS 2',3'-DIDEOXYCYTIDINE COMBINATION THERAPY, Journal of virology, 70(9), 1996, pp. 5922-5929
SIGNIFICANCE OF AMINO-ACID VARIATION AT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE RESIDUE-210 FOR ZIDOVUDINE SUSCEPTIBILITY
Authors: HARRIGAN PR KINGHORN I BLOOR S KEMP SD NAJERA I KOHLI A LARDER BA
Citation: Pr. Harrigan et al., SIGNIFICANCE OF AMINO-ACID VARIATION AT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE RESIDUE-210 FOR ZIDOVUDINE SUSCEPTIBILITY, Journal of virology, 70(9), 1996, pp. 5930-5934
VIROLOGICAL AND IMMUNOLOGICAL BENEFITS OF INITIAL COMBINATION THERAPYWITH ZIDOVUDINE AND ZALCITABINE OR DIDANOSINE COMPARED WITH ZIDOVUDINE MONOTHERAPY
Authors: SCHOOLEY RT RAMIREZRONDA C LANGE JMA COOPER DA LAVELLE J LEFKOWITZ L MOORE M LARDER BA STCLAIR M MULDER JW MCKINNIS R PENNINGTON KN HARRIGAN PR KINGHORN I STEEL H ROONEY JF RAY MG KURITZKES D RIVERAVASQUEZ C SANTANA J VANLEEUWEN R BOUCHER C REISS P VEENSTRA J KEET R PIERCE P HAAS D BARNES B LOEWENTHAL M DARCYEVANS C KEMP S KOHLI A MYERS R YEO J EMERY S ROMERO C ANDREWS J HANSON C SHORTINO D PATTISHALL K BARRY D
Citation: Rt. Schooley et al., VIROLOGICAL AND IMMUNOLOGICAL BENEFITS OF INITIAL COMBINATION THERAPYWITH ZIDOVUDINE AND ZALCITABINE OR DIDANOSINE COMPARED WITH ZIDOVUDINE MONOTHERAPY, The Journal of infectious diseases, 173(6), 1996, pp. 1354-1366
SIGNIFICANCE OF AMINO-ACID VARIATION AT RT CODON-210 FOR AZT SENSITIVITY
Authors: LARDER BA KINGHORN I BLOOR S KEMP SD NAJERA I KOHLI A HARRIGAN PR
Citation: Ba. Larder et al., SIGNIFICANCE OF AMINO-ACID VARIATION AT RT CODON-210 FOR AZT SENSITIVITY, Journal of acquired immune deficiency syndromes and human retrovirology, 10, 1995, pp. 14-14
VIROLOGICAL RESPONSE TO AZT 3TC COMBINATION THERAPY IN AZT-EXPERIENCED PATIENTS (TRIAL NUCB3002)/
Authors: HARRIGAN PR BLOOR S KINGHORN I LARDER BA
Citation: Pr. Harrigan et al., VIROLOGICAL RESPONSE TO AZT 3TC COMBINATION THERAPY IN AZT-EXPERIENCED PATIENTS (TRIAL NUCB3002)/, Journal of acquired immune deficiency syndromes and human retrovirology, 10, 1995, pp. 54-54
VIROLOGICAL RESPONSE TO AZT 3TC COMBINATION THERAPY IN AZT-NAIVE PATIENTS (TRIAL NUCB-3001)/
Authors: HARRIGAN PR KINGHORN I KOHLI A KEMP SD BLOOR S LARDER BA
Citation: Pr. Harrigan et al., VIROLOGICAL RESPONSE TO AZT 3TC COMBINATION THERAPY IN AZT-NAIVE PATIENTS (TRIAL NUCB-3001)/, Journal of acquired immune deficiency syndromes and human retrovirology, 10, 1995, pp. 56-56
RELATIONSHIPS BETWEEN SI NSI STATUS, VIRAL LOAD AND ENV SEQUENCE IN PATIENTS ENTERING A CLINICAL-TRIAL/
Authors: HARRIGAN PR KINGHORN I KOHLI A LARDER BA
Citation: Pr. Harrigan et al., RELATIONSHIPS BETWEEN SI NSI STATUS, VIRAL LOAD AND ENV SEQUENCE IN PATIENTS ENTERING A CLINICAL-TRIAL/, Journal of cellular biochemistry, 1995, pp. 191-191
POTENTIAL MECHANISM FOR SUSTAINED ANTIRETROVIRAL EFFICACY OF AZT-3TC COMBINATION THERAPY
Authors: LARDER BA KEMP SD HARRIGAN PR
Citation: Ba. Larder et al., POTENTIAL MECHANISM FOR SUSTAINED ANTIRETROVIRAL EFFICACY OF AZT-3TC COMBINATION THERAPY, Science, 269(5224), 1995, pp. 696-699
ACCUMULATION OF DOXORUBICIN AND OTHER LIPOPHILIC AMINES INTO LARGE UNILAMELLAR VESICLES IN RESPONSE TO TRANSMEMBRANE PH GRADIENTS
Authors: HARRIGAN PR WONG KF REDELMEIER TE WHEELER JJ CULLIS PR
Citation: Pr. Harrigan et al., ACCUMULATION OF DOXORUBICIN AND OTHER LIPOPHILIC AMINES INTO LARGE UNILAMELLAR VESICLES IN RESPONSE TO TRANSMEMBRANE PH GRADIENTS, Biochimica et biophysica acta, 1149(2), 1993, pp. 329-338
Risultati: 1-19 |